TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2025-01-30
• Target enrollment: 0
• Participant gender: All

Summary

A phase 1 dose escalation and expanded cohort study of TR115 in the treatment of adult patients with relapsed/refractory non-hodgkin's lymphoma or advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tarapeutics Science Inc.

Criteria

Key Inclusion Criteria:

• fully understand the procedures of the clinical study and participate voluntarily with signed and dated written informed consent form, comply with the requirements of the study protocol.

• males and/or females at least 18 years old when signing the informed consent form.

• tumor type criteria:

1. relapsed/refractory histologically or cytologically documented non-hodgkin's lymphoma must have received at least 1 prior systemic therapies, including but not limited as below: FL, DLBCL, PTCL-NOS, AITL, ALCL.

2. histologically or cytologically confirmed patients with advanced malignant solid tumors, eligible patients must have failed standard treatment, no standard treawtment, or not suitable for standard treatment at this stage as determined by the investigator.

• eastern cooperative oncology group performance status (ECOG) ≤2 at screening.

• life expectancy of at least 3 months.

• acceptable organ function: absolute neutrophil count (ANC)≥1.0×109/L (note: growth factor supports within 14 days of the first dose); platelet count (PLT)≥90×109/L （note: PLT≥70 × 109/L for patients with NHL and ≥50 × 109/L allowed in patients with bone marrow infiltration. no blood product transfusion is allowed within 14 days of the first dose); hemoglobin (Hb) ≥90g/L (note: Hb ≥80g/L for patients with NHL and ≥70g/L in patients with bone marrow infiltration. no blood product transfusion is allowed within 14 days of the first dose); INR or PT≤1.5×Upper limit of normal value (ULN), PTT≤1.5×ULN ；Total bilirubin (TBIL)≤1.5×ULN, AST and ALT≤2.5×ULN (note: ≤ 5 × ULN if there is liver involvement); Cr ≤1.5×ULN or CCr ≥50 ml/min (calculated by Cockcroft-Gault formula).

• fertile male and female must agree to use medically approved contraceptives during the study and within 6 months after the last dose of the study.

Key Exclusion Criteria:

• known or suspected allergies to any of the investigational drug compositon.

• medical history and surgical history excluded according to the protocol.

• any previous medical treatment history exclude from the protocol.

• abnormal laboratory results exclude from the protocol.

• pregnant and lactating women (currently breast-feeding or less than six months after delivery although not breast-feeding).

• subjects may not be able to complete the study due to poor compliance or other reasons, or unsuitable for the study by the investigator's judgment.